🔵🟠A Major Step for Early Oncodiagnostics: Liquid Biopsy Concept Successfully Validated!
At DIANA Biotechnologies, we have just completed a key phase of our oncodiagnostics project. Our feasibility study has confirmed that the technologies we developed for detecting somatic mutations perform with extraordinary precision even on real patient samples.
Why is the project so important? Lead Scientist of oncodiagnostics project, Monika Vilímová, will tell you!
🔵 Why does this matter?
”We focused on pancreatic cancer, one of the most challenging malignancies where early detection is absolutely critical. Our method focuses on detecting 4 key mutations in the KRAS gene, the primary driver of this disease.”
🟠 What is the technological breakthrough?
"To capture mutations in blood (liquid biopsy), especially in early stages, extreme sensitivity is required. The amount of tumor DNA in these fluids is minimal, but our assay can: Detect 1 copy of mutant DNA in a sea of 100,000 copies of normal DNA (sensitivity down to 0.001%) and achieve the same parameters in real patient blood samples as in controlled laboratory conditions.”
🔵Is the technology accessible?
”Our technology is accessible to all unlike methods such as NGS or digital PCR, our solution is built on a standard PCR platform. Thanks to our proprietary proteins and sophisticated assay design, we have created a method that is:
✅ Outstanding Sensitivity (outperforming PCR and NGS tests on the market).
✅ Cost-Effective (crucial for large-scale screening programs).
✅ Easy to Implement (can be used by virtually any laboratory).
This successful Proof of Concept opens the door to a future where liquid biopsy is a routine tool for earlier and more accurate cancer diagnostics.
A huge thank you to the entire team for their fantastic work and to the participating hospitals for their collaboration in sample collection!
The project „Feasibility study of PCR method for detection of somatic mutations in liquid biopsy“ was co-funded by the EU through the Operational programme TAC. The project aimed to verify technical and commercial feasibility of development of a PCR method for detection of somatic mutations relevant for application in oncodiagnostics.
At DIANA Biotechnologies, we have just completed a key phase of our oncodiagnostics project. Our feasibility study has confirmed that the technologies we developed for detecting somatic mutations perform with extraordinary precision even on real patient samples.
Why is the project so important? Lead Scientist of oncodiagnostics project, Monika Vilímová, will tell you!
🔵 Why does this matter?
”We focused on pancreatic cancer, one of the most challenging malignancies where early detection is absolutely critical. Our method focuses on detecting 4 key mutations in the KRAS gene, the primary driver of this disease.”
🟠 What is the technological breakthrough?
"To capture mutations in blood (liquid biopsy), especially in early stages, extreme sensitivity is required. The amount of tumor DNA in these fluids is minimal, but our assay can: Detect 1 copy of mutant DNA in a sea of 100,000 copies of normal DNA (sensitivity down to 0.001%) and achieve the same parameters in real patient blood samples as in controlled laboratory conditions.”
🔵Is the technology accessible?
”Our technology is accessible to all unlike methods such as NGS or digital PCR, our solution is built on a standard PCR platform. Thanks to our proprietary proteins and sophisticated assay design, we have created a method that is:
✅ Outstanding Sensitivity (outperforming PCR and NGS tests on the market).
✅ Cost-Effective (crucial for large-scale screening programs).
✅ Easy to Implement (can be used by virtually any laboratory).
This successful Proof of Concept opens the door to a future where liquid biopsy is a routine tool for earlier and more accurate cancer diagnostics.
A huge thank you to the entire team for their fantastic work and to the participating hospitals for their collaboration in sample collection!
The project „Feasibility study of PCR method for detection of somatic mutations in liquid biopsy“ was co-funded by the EU through the Operational programme TAC. The project aimed to verify technical and commercial feasibility of development of a PCR method for detection of somatic mutations relevant for application in oncodiagnostics.